Journal: Scientific reports

Article Title: Noninvasive intravital high-resolution imaging of pancreatic neuroendocrine tumours.

doi: 10.1038/s41598-019-51093-0

Figure Lengend Snippet: Figure 5. Sunitinib treatment results in tumour vessel regression and reduced RT2 tumour growth. (A) Treatment and imaging protocol. (B) Image panels showing representative RT2 tumours exposed to sham and Sunitinib treatment at indicated time-points. Tumour cells were visualized by scattered light (grey scale), and tumour vessels by Texas Red-70 kDa dextran administered to the circulation (Texas Red) (red). Bottom row represents merged images. Scale bars represents 50 μm. (C) Quantification of indicated tumour vascular parameters showing fold changes after one week (W3/W2) and two weeks (W4/W2) of control and Sunitinib treatment. (D) Graphs showing the growth of tumours during the entire study protocol. (E) Fold changes in tumour volume after two weeks of control and Sunitinib treatment. (control = 9, Sunitinib = 12). Statistics: (C) Mann-Whitney-Wilcoxon Test, median ± SD, (E) Student’s t-test mean ± SD; *P < 0.05, **P < 0.01,***P < 0.001.

Article Snippet: For Sunitinib treatment, Sunitinib (SelleckChem) was dissolved at 80 mg/ml in 100% DMSO (Sigma), allocated and frozen at −21 °C for up to 1 week.

Techniques: Imaging, Control, MANN-WHITNEY

Journal: Oncotarget

Article Title: The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

doi: 10.18632/oncotarget.19618

Figure Lengend Snippet: 786-O (A) and Caki-1 (B) cells were treated with single agent therapy, or in combination with sunitinib. Cellular viability was determined by CellTiter-Glo ® .

Article Snippet: After 5 weeks of treatment, mice in the vehicle cohort and mice in the sunitinib cohort were treated with the combination of sunitinib 40 mg/kg and abemaciclib 100 mg/kg (HY-16297, Medchemexpress) for an additional 4 weeks.

Techniques:

Journal: Oncotarget

Article Title: The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

doi: 10.18632/oncotarget.19618

Figure Lengend Snippet: 786-O cells were treated with DMSO (A) , sunitinib (B) , abemaciclib (C) , or abemaciclib + sunitinib (D) . Cells were stained for annexin V and positivity determined by flow cytometry.

Article Snippet: After 5 weeks of treatment, mice in the vehicle cohort and mice in the sunitinib cohort were treated with the combination of sunitinib 40 mg/kg and abemaciclib 100 mg/kg (HY-16297, Medchemexpress) for an additional 4 weeks.

Techniques: Staining, Flow Cytometry

Journal: Oncotarget

Article Title: The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

doi: 10.18632/oncotarget.19618

Figure Lengend Snippet: In 786-O cells (A) and Caki-1 cells (B) abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when abemaciclib is combined with sunitinib.

Article Snippet: After 5 weeks of treatment, mice in the vehicle cohort and mice in the sunitinib cohort were treated with the combination of sunitinib 40 mg/kg and abemaciclib 100 mg/kg (HY-16297, Medchemexpress) for an additional 4 weeks.

Techniques:

Journal: Oncotarget

Article Title: The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

doi: 10.18632/oncotarget.19618

Figure Lengend Snippet: 786-O cells were treated with DMSO (A) , sunitinib (B) , abemaciclib (C) , or abemaciclib + sunitinib (D) . Pictures were taken after 24 hours of treatment. Magnification factor is 20X.

Article Snippet: After 5 weeks of treatment, mice in the vehicle cohort and mice in the sunitinib cohort were treated with the combination of sunitinib 40 mg/kg and abemaciclib 100 mg/kg (HY-16297, Medchemexpress) for an additional 4 weeks.

Techniques:

Journal: Oncotarget

Article Title: The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

doi: 10.18632/oncotarget.19618

Figure Lengend Snippet: Mice with xenograft RCC tumors were treated with sunitinib or vehicle. (A) Tumor size in individual mice. Mice were treated with vehicle or sunitinib as labelled and tumor size measured with calipers. (B) Mean tumor size in each treatment cohort. Error bars are standard deviation. The trend lines are shown within each group. P-value is for difference in slope over the course of the therapy.

Article Snippet: After 5 weeks of treatment, mice in the vehicle cohort and mice in the sunitinib cohort were treated with the combination of sunitinib 40 mg/kg and abemaciclib 100 mg/kg (HY-16297, Medchemexpress) for an additional 4 weeks.

Techniques: Standard Deviation

Journal: Oncotarget

Article Title: The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

doi: 10.18632/oncotarget.19618

Figure Lengend Snippet: Mice with xenograft RCC tumors were first treated with sunitinib or vehicle. At the end of treatment, all mice were treated with combination abemaciclib/sunitinib. (A) Tumor size in individual mice. (B) Mean tumor size in each treatment cohort. Error bars represent standard deviation. The trend lines are shown within each group.

Article Snippet: After 5 weeks of treatment, mice in the vehicle cohort and mice in the sunitinib cohort were treated with the combination of sunitinib 40 mg/kg and abemaciclib 100 mg/kg (HY-16297, Medchemexpress) for an additional 4 weeks.

Techniques: Standard Deviation

Journal: Oncotarget

Article Title: The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

doi: 10.18632/oncotarget.19618

Figure Lengend Snippet: After a course of sunitinib, mice were subsequently treated with combination abemaciclib/sunitinib and tumor response determined by measurement with calipers. (A) Individual responses, each line represents an individual mouse. (B) Mean response of cohort. Error bars represent standard error of the mean.

Article Snippet: After 5 weeks of treatment, mice in the vehicle cohort and mice in the sunitinib cohort were treated with the combination of sunitinib 40 mg/kg and abemaciclib 100 mg/kg (HY-16297, Medchemexpress) for an additional 4 weeks.

Techniques:

Journal: Analytical Sciences

Article Title: Cell Analysis on Microfluidics Combined with Mass Spectrometry

doi: 10.2116/analsci.20r006

Figure Lengend Snippet: Fig. 9 Metabolites detected by microfluidic chip and MS. (A) Integrated multichannel microfluidic chip-MS for cell metabolism studies. Adapted with permission from Ref. 90, Copyright 2016, American Chemical Society. (B) Microfluidic device for cell culture, metabolite analysis and cytotoxicity assay. Adapted from Ref. 94 with permission from The Royal Society of Chemistry. (C) Schematic of the integrated microdevices for mimicking the tumor microenvironment. Adapted from Ref. 96 with permission from The Royal Society of Chemistry. (D) Schematic illustration of the microfluidic intestine-liver model. Adapted with permission from Ref. 97, Copyright 2017, Springer Nature.

Article Snippet: Cell culture Cell microenvironment mimicry Cell signaling Evaluation of drug permeability Absorption Toxicity Chemoresistance analysis Combination drug therapy evaluation Epinephrine Sunitinib Paclitaxel Cyclophosphamide 6-o-methylguanine Genistein and dacarbazine 23 98 106 94 99 97 Sample pretreating Sample desalting, separation and enrichment Vitamin E metabolism Methotrexate metabolism Cell signaling Cell signaling Peptide detection Serum glycomic profiles analysis Vitamin E Methotrexate Growth hormone Dihydroxyphenylalanine Gramicidin Glycans 17 95 24 60 82 107 Single-cell manipulation Heterogeneity analysis Single-cell lipid fingerprints, lipid heterogeneity of adherent single-cells Phospholipids 51, 58, and 108 Fig. 2 Schematic description of a microengineered human BBB model.

Techniques: Cell Culture, Cytotoxicity Assay

Journal: Human molecular genetics

Article Title: High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.

doi: 10.1093/hmg/ddx323

Figure Lengend Snippet: Figure 1. MiR-302/520 miRNA family increases susceptibility of GBM cells to sunitinib treatment. a) Overview

Article Snippet: Temozolomide and the multitargeted tyrosine kinase inhibitors sunitinib malate and axitinib were acquired from Selleckchem (Houston, USA) and stored at 20 C in DMSO.

Techniques:

Journal: Human molecular genetics

Article Title: High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.

doi: 10.1093/hmg/ddx323

Figure Lengend Snippet: Figure 3. Combination of miRNA-302a/520b expression with multitargeted tyrosine kinase inhibitors decreases GBM cell viability. U87 and DBTRG cells were transfected with 50 nM of miRNA-302a, miR-520b or

Article Snippet: Temozolomide and the multitargeted tyrosine kinase inhibitors sunitinib malate and axitinib were acquired from Selleckchem (Houston, USA) and stored at 20 C in DMSO.

Techniques: Expressing, Transfection

Journal: Human molecular genetics

Article Title: High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.

doi: 10.1093/hmg/ddx323

Figure Lengend Snippet: Figure 5. Cellular DNA content increases upon miR-302a transfection and treatment with multitargeted tyrosine kinase inhibitors. Cells were incubated with miR-302a or control miRNA (cel-miR-239b) mimics for

Article Snippet: Temozolomide and the multitargeted tyrosine kinase inhibitors sunitinib malate and axitinib were acquired from Selleckchem (Houston, USA) and stored at 20 C in DMSO.

Techniques: Transfection, Incubation, Control